• Advertise
  • Contact
Saturday, July 19, 2025
Bronx Voice News
  • Login
  • Home
    • About Us
  • Trump Administration
  • NYC Elections 2025
    • Public Advocate Candidates Forum
    • Comptroller Candidates Forum
    • Meet The Candidate Video Interview Series
  • Metro
  • U.S.
  • International
  • Opinion
  • Podcasts
  • Home
    • About Us
  • Trump Administration
  • NYC Elections 2025
    • Public Advocate Candidates Forum
    • Comptroller Candidates Forum
    • Meet The Candidate Video Interview Series
  • Metro
  • U.S.
  • International
  • Opinion
  • Podcasts
No Result
View All Result
New York Voice
No Result
View All Result
Home U.S.

FDA Approves First Nasal Spray for Treatment-Resistant Depression

Mymoena Kalinisan-Davids by Mymoena Kalinisan-Davids
January 21, 2025
in U.S.
FDA Approves First Nasal Spray for Treatment-Resistant Depression
Share on FacebookShare on Twitter

On Tuesday, January 21st, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato, as the first standalone treatment for individuals with treatment-resistant depression. This innovative medication, based on esketamine hydrochloride, a derivative of ketamine, offers a groundbreaking option for patients who have not responded to at least two conventional oral antidepressants.

Spravato was initially approved in May 2019 for use alongside oral antidepressants. However, the FDA’s latest decision allows it to be used independently, addressing a critical need for patients suffering from persistent depression symptoms such as prolonged sadness, low energy, sleep disturbances, and suicidal thoughts. According to Johnson & Johnson, this approval offers patients the flexibility to discontinue oral medications that may cause undesirable side effects, such as weight gain and sexual dysfunction.

The nasal spray demonstrates rapid results, with some patients reporting relief within 24 hours of the first dose. Dr. Gregory Mattingly, a physician involved in clinical trials, noted that Spravato’sunique mechanism allows for immediate activation of neural networks, a significant improvement over traditional antidepressants that may take weeks to show efficacy.

Despite its promise, the treatment is not without risks. Spravato can cause side effects, including dizziness, sedation, anxiety, and dissociation. To mitigate these concerns, the drug is administered exclusively in certified healthcare settings under the Spravato Risk Evaluation and Mitigation Strategy Program. Patients are monitored for at least two hours post-administration to ensure safety.

With an estimated one-third of the 21 million U.S. adults with major depression classified as treatment-resistant, the approval of Spravato is a significant milestone. Bill Martin, Johnson & Johnson’s neuroscience division head, emphasized that the drug’s approval paves the way for personalized treatment plans, potentially expanding its reach to more patients.

Spravato has already demonstrated commercial success, with 140,000 patients treated worldwide and $780 million in sales in 2024. Johnson & Johnson anticipates annual revenue from Spravatoto to reach between $1 billion and $5 billion, a good thing as the company faces upcoming patent expirations for other products.

This FDA approval marks a crucial advancement in addressing the unmet needs of individuals battling severe depression, providing hope and relief for many who have struggled without effective options.

Tags: DepressionDrugsFDAKetamineNasal SprayRegulation

Related Posts

ICE Granted Access to Medicaid Records Under Trump Administration Deal
Trump Administration

ICE Granted Access to Medicaid Records Under Trump Administration Deal

by Tamara Brown
July 17, 2025
U.S. Deports Convicted Migrants to Eswatini After Home Countries Refuse Entry
International

U.S. Deports Convicted Migrants to Eswatini After Home Countries Refuse Entry

by Lisa Miller
July 17, 2025
Supreme Court Decision Opens Door to U.S. Education Job Cuts
U.S.

Supreme Court Decision Opens Door to U.S. Education Job Cuts

by Tamara Brown
July 15, 2025
Heavy Rain Floods New York City and New Jersey, Leaving Damage and Delays
Metro

Heavy Rain Floods New York City and New Jersey, Leaving Damage and Delays

by Isabella Rodriguez
July 15, 2025
Over 1,300 State Department Employees Laid Off in Structural Overhaul
U.S.

Over 1,300 State Department Employees Laid Off in Structural Overhaul

by Lisa Miller
July 11, 2025

Translate

af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sundanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
en English
No Result
View All Result

VOICE and LAN Newspapers Retailers

  • NEWS CATEGORIES
  • Metro
  • Crime and Public Safety
  • Adams Adminstration
  • Education
  • School Safety
  • U.S.
  • International
  • QUICK LINKS
  • Home
  • Retail Locations
  • Advertise With Us
  • About Us
  • Contact

© 2024 Bronx Voice News. All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Metro
  • Crime and Public Safety
  • Adams Adminstration
  • Education
  • School Safety
  • U.S.
  • International
  • Newspaper Editions
  • Retail Locations
  • Advertise With Us
  • About Us
  • Contact

© 2024 Bronx Voice News. All Rights Reserved.

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?